MeiraGTx Holdings plc

MeiraGTx Holdings plc announced an agreement with Oberland Capital Management LLC for an investment of up to $400 million. This funding package includes up to $375 million in non-dilutive capital through capped royalty payments on certain products and up to $25 million in equity. The capital will support the potential commercialization of the company's late-stage programs for X-linked retinitis pigmentosa (XLRP) and radiation-induced xerostomia.

MeiraGTx Holdings plc announced that its Compensation Committee approved equity awards for Penny Fleck in connection with her employment as Chief Development Officer. These awards were granted as an inducement material to her new employment, in accordance with Nasdaq Listing Rule 5635(c)(4). Ms. Fleck received non-qualified stock options to purchase 100,000 shares at an exercise price of $9.97, and 100,000 time-based restricted stock units (RSUs).

MeiraGTx Holdings plc announced significant strategic developments, including a collaboration with Eli Lilly and Company for ophthalmology gene therapies, providing $75.0 million upfront and up to $400.0 million in milestones. The company also entered a strategic collaboration with Hologen Limited for CNS gene therapies, involving a $200.0 million upfront payment commitment. Additionally, MeiraGTx reacquired the RPGR Product from Janssen Pharmaceuticals for an upfront cash purchase price of $25.0 million. For Q1 2026, the company reported a net loss of $(46.3) million, with total revenue of $0.293 million.

MeiraGTx Holdings plc announced its first quarter 2026 financial and operational results, highlighted by the re-acquisition of full rights to botaretigene sparoparvovec (bota-vec) for X-linked retinitis pigmentosa from Johnson & Johnson for $25 million upfront. The company also received FDA Breakthrough Therapy Designation for AAV2-hAQP1 for radiation-induced xerostomia, with positive three-year Phase 1 data. Financially, MeiraGTx reported a net loss of $46.3 million, an increase from $40.0 million in Q1 2025, but strengthened its balance sheet with a $100 million public offering, extending its cash runway into the second half of 2028.

MeiraGTx Holdings plc announced strong operational and financial results for Q1 2026, highlighted by the reacquisition of full rights to botaretigene sparoparvovec (bota-vec) for X-linked retinitis pigmentosa from Johnson & Johnson. The company also received FDA Breakthrough Therapy Designation for AAV2-hAQP1 for radiation-induced xerostomia, supported by positive three-year Phase 1 data. MeiraGTx strengthened its balance sheet with $100 million in gross proceeds from an equity offering, extending its cash runway into the second half of 2028. Despite a net loss of $46.3 million for the quarter, these strategic moves position the company for potential regulatory approvals and launches of two wholly-owned therapies within the next two years.

MeiraGTx Holdings plc completed the initial closing of its strategic collaboration with Hologen Limited on April 20, 2026. This collaboration involved amendments to the existing Neuro and Manufacturing Framework Agreements and the execution of a new Collaboration and License Agreement. The partnership is focused on the research, development, manufacture, and commercialization of MeiraGTx's investigational gene therapies, including AAV-GAD for Parkinson's disease and AAV-BDNF for genetic obesity disorders.

MeiraGTx Holdings plc entered into an underwriting agreement to sell 11,111,111 ordinary shares at an offering price of $9.00 per share. The company expects to receive net proceeds of approximately $93.3 million from this offering. These funds are intended for general corporate purposes, including working capital and capital expenditures. MeiraGTx believes the proceeds, combined with existing cash, will fund its operating expenses and capital expenditure requirements into the second half of 2028.

MeiraGTx Holdings plc announced the pricing of an underwritten offering of 11,111,111 ordinary shares at $9.00 per share. The offering is expected to generate approximately $100 million in gross proceeds for the company. MeiraGTx believes these funds, combined with existing cash, will be sufficient to cover operating expenses and capital expenditures, including potential commercial launches, into the second half of 2028. The offering is anticipated to close around April 17, 2026.

MeiraGTx Holdings plc acquired a gene therapy product for X-linked retinitis pigmentosa (RPGR Product) from Janssen Pharmaceuticals, Inc. The acquisition includes an upfront cash payment of $25 million. MeiraGTx will also pay a contingent consideration of $50 million upon achieving US regulatory approval and $250 million in aggregate US net sales, along with mid-teens percentage royalties on future global net sales starting July 2029. This strategic acquisition enhances MeiraGTx's pipeline in ocular gene therapy.

MeiraGTx Holdings plc announced positive 3-year data from its Phase 1 AQUAx clinical study of AAV-hAQP1 for radiation-induced xerostomia. The treatment demonstrated safety and tolerability, with no dose-limiting toxicities or treatment-related serious adverse events. Significant improvements in Xerostomia Questionnaire scores observed at 12 months were sustained through 36 months, indicating long-term efficacy for patients.